top of page

Insights & Updates


Surviving the Phase II Cliff: Why So Many Promising Drugs Fail — and What We Can Do About It
For translational leaders, generating decision-quality data before risking millions in clinical trials is crucial. De-Risk Antibody Development with Tissue Insights Platform.
Featured
Search


Offspring Biosciences Special Feature: ✨Best in Stain ✨
Beyond their visual impact, these images represent something far more important: the power of spatial biology to reveal how biology truly functions within human tissue. #SpatialBiology #ScienceAsArt #Microscopy #SpatialBiology #Biotech
evadanielson55
Mar 312 min read


Validating CNS Therapeutics
Human Tissue Analysis in CNS drug development helps to bridge the translational gap and de-risk clinical development. New research on Alzheimers Disease, Palsy, Parkinsons, Multi System Atrophy and more offer insights into treatment development.
evadanielson55
Jan 274 min read


How Life Science Companies Can Receive Support In Their Work
Offspring Biosciences offers support services for businesses in preclinical and clinical drug development. – We help our customers make new drugs available to patients faster, safer, and at a lower cost, says Anders Dahlstrand, CEO of the company. Offspring Biosciences operates in the rapidly growing CRO industry (Contract Research Organization) and assists pharmaceutical and biotech companies by conducting preclinical and clinical studies required for regulatory approvals. O
Offspring Biosciences
Feb 9, 20242 min read


Offspring Biosciences in research collaboration developing alpha-synuclein PET ligand
New publication, “Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein” together with Karolinska Institutet, Andrea Varrone research group. The approach used in this study also shows that TMAs are a useful tool for the evaluation of ligands in tissue from different proteinopathies, using both fluorescence and autoradiographic assays https://doi.org/10.1016/j.brainres.2020.147131 The neuropathological hallmark o
-
Sep 16, 20211 min read


Developing a new drug is a long and costly process with many pitfalls
Most projects are closed down before the drug has reached the market. With the support of Offspring Bioscience's unique expertise in tissue analysis, pharmaceutical companies significantly improve the odds of success "Our unique ability to plan and carry out such analyses is based on the experience we have built up over a long period of time through our work on pharmaceutical projects in the pharmaceutical industry. With efficient methods and refined analytical techniques,
-
Sep 16, 20211 min read
bottom of page
